Shield Therapeutics ROA 2024

Shield Therapeutics Aktienanalyse

What does Shield Therapeutics do?

The company Shield Therapeutics PLC is a renowned British pharmaceutical conglomerate, founded in 2008. Based in Gateshead, England, Shield Therapeutics specializes in the development and marketing of pharmaceutical products, with a particular focus on iron deficiency anemia. The company also has a strong presence in Europe and Asia. Shield Therapeutics' business model is to provide high-quality and innovative medical solutions to improve people's health and well-being. The company continuously researches new products to better cater to the needs of patients and doctors. The focus of Shield Therapeutics is on combating iron deficiency anemia, a severe blood disorder caused by a lack of iron in the body. Iron deficiency can be attributed to various factors, such as inadequate food intake, blood loss, or iron deficiency accumulation due to diseases. This anemia can lead to a range of symptoms, including fatigue, weak muscles, and dizziness. Long-term consequences can include life-threatening complications such as heart failure and strokes. Shield Therapeutics offers various products that can be used to treat iron deficiency anemia, such as Feraccru (in injection form) and Accrufer / Accrufer Tablets (in tablet form). Feraccru is an orally absorbed iron preparation indicated for the treatment of anemia in adults with iron deficiency anemia. Accrufer / Accrufer Tablets is an iron salt complex that is rapidly absorbed and shows high efficacy. The company also has its own research and development department, which focuses on researching innovative therapies and treatment methods. Shield Therapeutics actively participates in clinical research and the development of new therapeutic options aimed at improving the quality of life for people with iron deficiency anemia. More recently, Shield Therapeutics has also ventured into other disease areas. The company has developed clinical studies in collaboration with a top 10 pharmaceutical company to modify atherosclerosis through iron chelators. This is a groundbreaking research field that aims to develop advanced therapies for the treatment of infertility and chronic obstructive pulmonary disease (COPD). Overall, Shield Therapeutics has experienced strong growth in recent years and has solidified its position as a leading provider of pharmaceutical products for the treatment of iron deficiency anemia. The company has developed a wide range of products and can rely on a strong research and development department that constantly faces new challenges and offers innovative solutions for a variety of health issues. If Shield Therapeutics continues to be successful, it will undoubtedly continue to play a significant role in the industry. Answer: The company Shield Therapeutics specializes in the development and marketing of pharmaceutical products, with a particular focus on iron deficiency anemia. Shield Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Shield Therapeutics's Return on Assets (ROA)

Shield Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Shield Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Shield Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Shield Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Shield Therapeutics stock

What is the Return on Assets (ROA) of Shield Therapeutics this year?

The Return on Assets (ROA) of Shield Therapeutics is -0.68 undefined this year.

What was the ROA of Shield Therapeutics compared to the previous year?

The ROA of Shield Therapeutics has increased by -63.53% compared to the previous year.

What consequences do high ROA have for investors of Shield Therapeutics?

A high ROA is advantageous for investors of Shield Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Shield Therapeutics?

A low ROA can be unfavorable for investors of Shield Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Shield Therapeutics affect the company?

An increase in ROA of Shield Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Shield Therapeutics impact the company?

A reduction in the ROA of Shield Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Shield Therapeutics?

Some factors that can influence the ROA of Shield Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Shield Therapeutics important for investors?

The ROA of Shield Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Shield Therapeutics take to improve ROA?

To improve ROA, Shield Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Shield Therapeutics pay?

Over the past 12 months, Shield Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Shield Therapeutics is expected to pay a dividend of 0 GBP.

What is the dividend yield of Shield Therapeutics?

The current dividend yield of Shield Therapeutics is .

When does Shield Therapeutics pay dividends?

Shield Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Shield Therapeutics?

Shield Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Shield Therapeutics?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Shield Therapeutics located?

Shield Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Shield Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Shield Therapeutics from 10/22/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 10/22/2024.

When did Shield Therapeutics pay the last dividend?

The last dividend was paid out on 10/22/2024.

What was the dividend of Shield Therapeutics in the year 2023?

In the year 2023, Shield Therapeutics distributed 0 GBP as dividends.

In which currency does Shield Therapeutics pay out the dividend?

The dividends of Shield Therapeutics are distributed in GBP.